Log in
Pathology · Additional topics

Thyroid tumors

Tumores glandulae thyreoideae

Thyroid tumors require a multidisciplinary approach, including radionuclide imaging for node evaluation and staging. The critical stage of patient management is postoperative hormonal suppression and careful instrumental monitoring to rule out recurrences and bone metastases.

ScintigraphyUsed for nodule diagnosis, staging of neuroendocrine tumors, and medullary carcinoma
LevothyroxineSuppresses TSH-dependent growth of residual differentiated cancer cells
RecurrencesAbout 95% of recurrences occur within the first 2 years after completion of treatment
MetastasisThyroid cancer frequently metastasizes to bone tissue
3 min readFor medical studentsUpdated 10.10.2026
Material prepared by WhiteCoat Pro editorial team based on platform study guidesPending instructor review

Instrumental Diagnostics and Staging

Primary evaluation and staging of neoplasms rely heavily on radionuclide diagnostics. Scintigraphy is a key tool for:

  • Assessing the functional activity and nature of thyroid nodules.
  • Diagnosing and accurately staging neuroendocrine tumors, specifically medullary thyroid carcinoma.

In modern personalized oncology, radiologists need a deep understanding of anatomy, metastatic pathways, and must consider radiomics (radiomics) and genomics data. A diagnosis of a malignant process or its progression should be made only with a high degree of certainty to avoid overdiagnosis (overdiagnose).

Hormone Therapy in Cancer

Following surgical treatment for tumors, patients require specific medical support. Thyroid hormone medications serve a dual function:

  1. Levothyroxine sodium is the drug of choice for differentiated thyroid cancer. It is used not only as replacement therapy, but also for suppression. The main goal is to inhibit TSH-dependent growth of residual tumor cells.
  2. Liothyronine and thyreoidin also have oncological thyroid pathology in their indications and can be used for diagnostic purposes (e.g., suppression tests).
Test your knowledge on the topicTasks from the "Pathological Anatomy" course bank — instant answers and explanations.

Post-Treatment Follow-Up and Recurrence Monitoring

A history of a malignant neoplasm requires close attention to any persistent or prolonged patient complaints (lethargy, weight loss).

  • Statistics: 95% of recurrences develop within the first 2 years after therapy. Meanwhile, tumor markers remain negative in one-third of patients.
  • Tactics: CT monitoring is justified during the first two years. An interval of 6–12 months does not worsen the prognosis, although for large tumors, an empirical shortening of the interval between examinations is entirely appropriate.
  • Whole-body imaging: When recurrence is suspected, whole-body CT, MRI, or PET/CT is increasingly used. The main risk of such methods is obtaining false-positive results or detecting untreatable recurrences.

Upon confirmation of recurrence, modern cytotoxic chemotherapy shows high efficacy (cure rate exceeds 90%).

Specifics of Detecting Bone Metastases

Thyroid tumors tend to metastasize to the bones. When an oncological patient presents with acute bone pain, radionuclide imaging (bone scan) serves as the primary screening method.

However, the method has limitations: visualization of the lesion requires a pronounced osteoblastic response (osteoblastic response). If the metastasis does not provoke such a reaction, the scintigram may be false-negative. In such situations, when the clinical picture persists and the radionuclide test is clear, MRI becomes the method of choice, capable of detailing areas of low signal in the vertebral bodies and the threat of spinal cord compression.

Class and exam questions

Why is levothyroxine prescribed after removal of differentiated thyroid cancer?

The drug is used not only to replace hormone deficiency, but also as suppressive therapy to inhibit TSH-dependent growth of any remaining cancer cells.

How often do recurrences occur and when should they be expected?

The vast majority of recurrences (95%) occur within the first two years after completing primary treatment. Regular CT monitoring is indicated during this period.

Does a bone scan always detect bone metastases?

No, a sufficient tissue osteoblastic response is required for successful detection. If absent, the result will be false-negative, and an MRI will be needed to clarify the diagnosis.

What should be done if whole-body imaging results are equivocal?

Diagnosing metastasis is a heavy blow for the patient. If the picture is atypical and there is no high degree of certainty, making the diagnosis should be postponed to avoid overdiagnosis.

Unclear? Ask the AIThe AI tutor has reviewed the material on "Thyroid Tumors" and will explain it in simple terms.

What else to study on this topic

  • Pathophysiology of Osteoblastic Response in Bone Metastases
  • Radiomics and Genomics in Personalized Oncology
  • Specifics of Whole-Body PET/CT in Searching for Occult Recurrences
  • Mechanisms of Action of Cytotoxic Chemotherapy in Cancer Recurrences
  • Diagnostic Algorithms for Medullary Thyroid Carcinoma

Master the entire topic in the "Pathological Anatomy" course

This is a summary. The course covers everything tested in classes and exams.

  • Complete Study Guide on "Thyroid Tumors" and 4,414 More Subject Pages
  • Assignments and quizzes after every topic — just like in a colloquium
  • AI tutor answers questions on the topic anytime
  • 153 video lessons on the subject

Other topics in the "Additional Topics" section

Free video lessons: pathological anatomyShort lessons with study notes — no registration required.

Watch lessons

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.